2m 2m 2m 2m 2m 2m 2m
Cellyan Biotec-A (HKPD)
NASDAQ
$0.41-$0.0007 (-0.17%)
Price as of Aug 21, 2026 4:00 PM EDT- $613,050.00Market Cap
- -60.72%1-Year Change
- Medical DistributionIndustry
Cellyan Biotec-A (HKPD)
$0.41-$0.0007 (-0.17%)
Annual
Quarterly
03/31/2026 | 03/31/2025 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 13.4M -33.87% | 20.3M N/A | |
Cost of Revenue | 12.0M -32.69% | 17.9M N/A | |
Gross Profit | 1.4M -42.60% | 2.4M N/A | |
Sales and Marketing Expense | 2.4M +8.09% | 2.2M N/A | |
Research and Development Expense | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | 86,536 +14.21% | 75,766 N/A | |
Total Operating Expenses | 2.4M +8.09% | 2.2M N/A | |
Operating Profit | -2.4M +4.46% | -2.3M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 5,327 +263.37% | 1,466 N/A | |
Income before Taxes | -1.1M +4,098.56% | -27,056 N/A | |
Income Taxes | 7,666 -87.86% | 63,168 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -1.1M +4,098.56% | -27,056 N/A | |
Net Income from Continuing Operations Applicable to Common | -1.1M +4,098.56% | -27,056 N/A | |
Basic EPS and Net Income | -0.07 +2,200.00% | -0.003 N/A | |
Diluted EPS and Net Income | -0.07 +2,200.00% | -0.003 N/A | |
Basic Weighted Average Shares | 16.3M +60.21% | 10.2M N/A | |
Diluted Weighted Average Shares | 16.3M +60.21% | 10.2M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 221,841 -70.37% | 748,721 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 221,841 -70.37% | 748,721 N/A | |
Total Current Assets | 12.3M +41.32% | 8.7M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 58,671 -47.26% | 111,245 N/A | |
Total Long-Term Assets | 510,771 -25.99% | 690,171 N/A | |
Total Assets | 12.8M +36.39% | 9.4M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 3.2M +9.55% | 2.9M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 65,275 -95.68% | 1.5M N/A | |
Total Liabilities | 3.3M -26.34% | 4.4M N/A | |
Retained Earnings | 368,089 -75.53% | 1.5M N/A | |
Total Stockholders Equity | 9.6M +92.06% | 5.0M N/A | |
Total Shares Outstanding | 16.3M +48.64% | 11.0M N/A | |
Cash Flow | |||
Cash from Operating Activities | -751,602 -232.04% | 569,214 N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | 857,457 +134.93% | -2.5M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | -630,225 -131.59% | 2.0M N/A | |
Financials Ratio | |||
Gross Margin | 10.32% N/A | N/A N/A | |
Operating Margin | -17.77% N/A | N/A N/A | |
Return on Assets | -10.21% N/A | N/A N/A | |
Return on Equity | -15.59% N/A | N/A N/A | |
Revenue Growth | -33.87% N/A | N/A N/A | |
Current Ratio | 3.86 N/A | N/A N/A | |
Cash Ratio | 0.07 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow